nach oben

Erschienen in:

22.12.2022

Hypoxia signaling in hepatocellular carcinoma: Challenges and therapeutic opportunities

verfasst von: Shant Qinxiang Sin, Chakrabhavi Dhananjaya Mohan, Robby Miguel Wen-Jing Goh, Mingliang You, Siddaiah Chandra Nayak, Lu Chen, Gautam Sethi, Kanchugarakoppal Subbegowda Rangappa, Lingzhi Wang

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers with a relatively high cancer-related mortality. The uncontrolled proliferation of HCC consumes a significant amount of oxygen, causing the development of a hypoxic tumor microenvironment (TME). Hypoxia-inducible factors (HIFs), crucial regulators in the TME, activate several cancer hallmarks leading to the hepatocarcinogenesis of HCC and resistance to current therapeutics. As such, HIFs and their signaling pathways have been explored as potential therapeutic targets for the future management of HCC. This review discusses the current understanding of the structure and function of HIFs and their complex relationship with the various cancer hallmarks. To address tumor hypoxia, this review provides an insight into the various potential novel therapeutic agents for managing HCC, such as hypoxia-activated prodrugs, HIF inhibitors, nanomaterials, antisense oligonucleotides, and natural compounds, that target HIFs/hypoxic signaling pathways in HCC. Because of HCC’s relatively high incidence and mortality rates in the past decades, greater efforts should be put in place to explore novel therapeutic approaches to improve the outcome for HCC patients.

World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report 2018. Diet, n., physical activity and liver cancer. Available at dietandcancerreport.org. Accessed 02/23/2022

Arora, L., Mohan, C. D., Yang, M. H., Rangappa, S., Deivasigamani, A., Kumar, A. P., et al. (2021). Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) abrogates tumor progression in hepatocellular carcinoma and multiple myeloma preclinical models by regulating the STAT3 signaling pathway. Cancers (Basel), 13(21). https://doi.org/10.3390/cancers13215479.

Mohan, C. D., Yang, M. H., Rangappa, S., Chinnathambi, A., Alharbi, S. A., Alahmadi, T. A., et al. (2022). 3-Formylchromone counteracts STAT3 signaling pathway by elevating SHP-2 expression in hepatocellular carcinoma. Biology, 11(1). https://doi.org/10.3390/biology11010029.

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A cancer journal for clinicians, 71(3), 209–249.PubMed

McGlynn, K. A., Petrick, J. L., & El-Serag, H. B. (2021). Epidemiology of hepatocellular carcinoma. Hepatology, 73, 4–13.PubMedCrossRef

Mastron, J. K., Siveen, K. S., Sethi, G., & Bishayee, A. (2015). Silymarin and hepatocellular carcinoma: A systematic, comprehensive, and critical review. Anti-Cancer Drugs, 26(5), 475–486. https://doi.org/10.1097/cad.0000000000000211CrossRefPubMed

Raghunath, A., Sundarraj, K., Arfuso, F., Sethi, G., & Perumal, E. (2018). Dysregulation of Nrf2 in hepatocellular carcinoma: Role in cancer progression and chemoresistance. Cancers (Basel), 10(12), 481.PubMedCrossRef

Forner, A., Reig, M., & Bruix, J. (2018). Hepatocellular carcinoma. Lancet, 391(10127), 1301–1314. https://doi.org/10.1016/s0140-6736(18)30010-2CrossRefPubMed

Mohan, C. D., Rangappa, S., Nayak, S. C., Sethi, G., & Rangappa, K. S. (2021). Paradoxical functions of long noncoding RNAs in modulating STAT3 signaling pathway in hepatocellular carcinoma. Biochimica et Biophysica Acta - Reviews on Cancer, 1876(1), 188574. https://doi.org/10.1016/j.bbcan.2021.188574CrossRefPubMed

10.

Sajith, A. M., Narasimhamurthy, K. H., Shanmugam, M. K., Rangappa, S., Chandra Nayak, S., Chinnathambi, A., et al. (2021). Pyrimidine-2,4-dione targets STAT3 signaling pathway to induce cytotoxicity in hepatocellular carcinoma cells. Bioorganic & Medicinal Chemistry Letters, 50, 128332. https://doi.org/10.1016/j.bmcl.2021.128332CrossRef

11.

Mohan, C. D., Kim, C., Siveen, K. S., Manu, K. A., Rangappa, S., Chinnathambi, A., et al. (2021). Crocetin imparts antiproliferative activity via inhibiting STAT3 signaling in hepatocellular carcinoma. IUBMB Life, 73(11), 1348–1362. https://doi.org/10.1002/iub.2555CrossRefPubMed

12.

Colagrande, S., Inghilesi, A. L., Aburas, S., Taliani, G. G., Nardi, C., & Marra, F. (2016). Challenges of advanced hepatocellular carcinoma. World Journal of Gastroenterology, 22(34), 7645.PubMedPubMedCentralCrossRef

13.

Swamy, S. G., Kameshwar, V. H., Shubha, P. B., Looi, C. Y., Shanmugam, M. K., Arfuso, F., et al. (2017). Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma. Targeted Oncology, 12(1), 1–10. https://doi.org/10.1007/s11523-016-0452-7CrossRefPubMed

14.

Chen, X., Tang, F.-R., Arfuso, F., Cai, W.-Q., Ma, Z., Yang, J., et al. (2020). The emerging role of long non-coding RNAs in the metastasis of hepatocellular carcinoma. Biomolecules, 10(1), 66.CrossRef

15.

Keerthy, H. K., Mohan, C. D., Siveen, K. S., Fuchs, J. E., Rangappa, S., Sundaram, M. S., et al. (2014). Novel synthetic biscoumarins target tumor necrosis factor-α in hepatocellular carcinoma in vitro and in vivo. Journal of Biological Chemistry, 289(46), 31879–31890. https://doi.org/10.1074/jbc.M114.593855CrossRefPubMedPubMedCentral

16.

Cabibbo, G., Cucchetti, A., Cammà, C., Casadei-Gardini, A., Celsa, C., Rizzo, G. E. M., et al. (2019). Outcomes of hepatocellular carcinoma patients treated with sorafenib: A meta-analysis of Phase III trials. Future Oncology, 15(29), 3411–3422. https://doi.org/10.2217/fon-2019-0287CrossRefPubMed

17.

Méndez-Blanco, C., Fondevila, F., García-Palomo, A., González-Gallego, J., & Mauriz, J. L. (2018). Sorafenib resistance in hepatocarcinoma: Role of hypoxia-inducible factors. Experimental & Molecular Medicine, 50(10), 1–9. https://doi.org/10.1038/s12276-018-0159-1CrossRef

18.

Paskeh, M. D. A., Mirzaei, S., Ashrafizadeh, M., Zarrabi, A., & Sethi, G. (2021). Wnt/β-catenin signaling as a driver of hepatocellular carcinoma progression: An emphasis on molecular pathways. Journal of Hepatocellular Carcinoma, 8, 1415.CrossRef

19.

Mohan, C. D., Anilkumar, N. C., Rangappa, S., Shanmugam, M. K., Mishra, S., Chinnathambi, A., et al. (2018). Novel 1,3,4-oxadiazole induces anticancer activity by targeting NF-κB in hepatocellular carcinoma cells. Frontiers in Oncology, 8, 42. https://doi.org/10.3389/fonc.2018.00042CrossRefPubMedPubMedCentral

20.

Lee, J. H., Mohan, C. D., Deivasigamani, A., Jung, Y. Y., Rangappa, S., Basappa, S., et al. (2020). Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma. Journal of Advanced Research, 26, 83–94. https://doi.org/10.1016/j.jare.2020.07.004CrossRefPubMedPubMedCentral

21.

Dai, X., Ahn, K. S., Kim, C., Siveen, K. S., Ong, T. H., Shanmugam, M. K., et al. (2015). Ascochlorin, an isoprenoid antibiotic inhibits growth and invasion of hepatocellular carcinoma by targeting STAT3 signaling cascade through the induction of PIAS3. Molecular Oncology, 9(4), 818–833. https://doi.org/10.1016/j.molonc.2014.12.008CrossRefPubMedPubMedCentral

22.

Mohan, C. D., Bharathkumar, H., Bulusu, K. C., Pandey, V., Rangappa, S., Fuchs, J. E., et al. (2014). Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo. Journal of Biological Chemistry, 289(49), 34296–34307. https://doi.org/10.1074/jbc.M114.601104CrossRefPubMedPubMedCentral

23.

Vaid, A. K., Gupta, A., & Momi, G. (2021). Overall survival in stage IV EGFR mutation-positive NSCLC: Comparing first-, second- and third-generation EGFR-TKIs (Review). International Journal of Oncology, 58(2), 171–184. https://doi.org/10.3892/ijo.2021.5168CrossRefPubMed

24.

Yu, Y., Zeng, D., Ou, Q., Liu, S., Li, A., Chen, Y., et al. (2019). Association of survival and immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: A meta-analysis and individual patient-level analysis. JAMA Network Open, 2(7), e196879. https://doi.org/10.1001/jamanetworkopen.2019.6879CrossRefPubMedPubMedCentral

25.

Stock-Martineau, S., Laurie, K., McKinnon, M., Zhang, T., & Wheatley-Price, P. (2021). Evolution of systemic treatment uptake and survival in advanced non-small cell lung cancer. Current Oncology, 28(1), 60–68.CrossRef

26.

Or, M., Liu, B., Lam, J., Vinod, S., Xuan, W., Yeghiaian-Alvandi, R., et al. (2021). A systematic review and meta-analysis of treatment-related toxicities of curative and palliative radiation therapy in non-small cell lung cancer. Science and Reports, 11(1), 5939. https://doi.org/10.1038/s41598-021-85131-7CrossRef

27.

Ma, Z., Wang, L. Z., Cheng, J. T., Lam, W. S. T., Ma, X., Xiang, X., et al. (2021). Targeting hypoxia-inducible factor-1-mediated metastasis for cancer therapy. Antioxidants & Redox Signaling, 34(18), 1484–1497. https://doi.org/10.1089/ars.2019.7935CrossRef

28.

Guo, Y., Xiao, Z., Yang, L., Gao, Y., Zhu, Q., Hu, L., et al. (2020). Hypoxia-inducible factors in hepatocellular carcinoma. Oncology Reports, 43(1), 3–15.PubMed

29.

Chen, C., & Lou, T. (2017). Hypoxia inducible factors in hepatocellular carcinoma. Oncotarget, 8(28), 46691.PubMedPubMedCentralCrossRef

30.

Bowyer, C., Lewis, A. L., Lloyd, A. W., Phillips, G. J., & Macfarlane, W. M. (2017). Hypoxia as a target for drug combination therapy of liver cancer. Anti-Cancer Drugs, 28(7), 771.PubMedPubMedCentralCrossRef

31.

Manoochehri Khoshinani, H., Afshar, S., & Najafi, R. (2016). Hypoxia: A double-edged sword in cancer therapy. Cancer Investigation, 34(10), 536–545.PubMedCrossRef

32.

Kabakov, A. E., & Yakimova, A. O. (2021). Hypoxia-induced cancer cell responses driving radioresistance of hypoxic tumors: Approaches to targeting and radiosensitizing. Cancers (Basel), 13(5), 1102.PubMedCrossRef

33.

Harada, H. (2016). Hypoxia-inducible factor 1–mediated characteristic features of cancer cells for tumor radioresistance. Journal of Radiation Research, 57(S1), i99–i105.PubMedPubMedCentralCrossRef

34.

Doktorova, H., Hrabeta, J., Khalil, M. A., & Eckschlager, T. (2015). Hypoxia-induced chemoresistance in cancer cells: The role of not only HIF-1. Biomedical papers of the Medical Faculty of the University Palacky Olomouc Czech Republic, 159(2), 166–77.

35.

Roy, S., Kumaravel, S., Sharma, A., Duran, C. L., Bayless, K. J., & Chakraborty, S. (2020). Hypoxic tumor microenvironment: Implications for cancer therapy. Experimental Biology and Medicine, 245(13), 1073–1086.PubMedPubMedCentralCrossRef

36.

Dai, X., Ahn, K. S., Wang, L. Z., Kim, C., Deivasigamni, A., Arfuso, F., et al. (2016). Ascochlorin enhances the sensitivity of doxorubicin leading to the reversal of epithelial-to-mesenchymal transition in hepatocellular carcinoma. Molecular Cancer Therapeutics, 15(12), 2966–2976. https://doi.org/10.1158/1535-7163.mct-16-0391CrossRefPubMed

37.

Dai, X., Wang, L., Deivasigamni, A., Looi, C. Y., Karthikeyan, C., Trivedi, P., et al. (2017). A novel benzimidazole derivative, MBIC inhibits tumor growth and promotes apoptosis via activation of ROS-dependent JNK signaling pathway in hepatocellular carcinoma. Oncotarget, 8(8), 12831–12842. https://doi.org/10.18632/oncotarget.14606CrossRefPubMedPubMedCentral

38.

Lee, J. H., Mohan, C. D., Shanmugam, M. K., Rangappa, S., Sethi, G., Siveen, K. S., et al. (2020). Vitexin abrogates invasion and survival of hepatocellular carcinoma cells through targeting STAT3 signaling pathway. Biochimie, 175, 58–68. https://doi.org/10.1016/j.biochi.2020.05.006CrossRefPubMed

39.

Somu, C., Mohan, C. D., Ambekar, S., Dukanya Rangappa, S., Baburajeev, C. P., et al. (2020). Identification of a novel 1,2 oxazine that can induce apoptosis by targeting NF-κB in hepatocellular carcinoma cells. Biotechnology Reports (Amst), 25, e00438. https://doi.org/10.1016/j.btre.2020.e00438CrossRef

40.

Lin, C.-A., Chang, L.-L., Zhu, H., He, Q.-J., & Yang, B. (2018). Hypoxic microenvironment and hepatocellular carcinoma treatment. Hepatoma Research, 4, 26.CrossRef

41.

Santhakumar, C., Gane, E. J., Liu, K., & McCaughan, G. W. (2020). Current perspectives on the tumor microenvironment in hepatocellular carcinoma. Hepatology International, 14(6), 947–957.PubMedCrossRef

42.

Xiong, X. X., Qiu, X. Y., Hu, D. X., & Chen, X. Q. (2017). Advances in hypoxia-mediated mechanisms in hepatocellular carcinoma. Molecular Pharmacology, 92(3), 246–255.PubMedCrossRef

43.

Han, D., Yang, P., Qin, B., Ji, G., Wu, Y., Yu, L., et al. (2021). Upregulation of Nogo-B by hypoxia inducible factor-1 and activator protein-1 in hepatocellular carcinoma. Cancer Science, 112(7), 2728.PubMedPubMedCentralCrossRef

44.

Chiu, D. K. C., Xu, I. M. J., Lai, R. K. H., Tse, A. P. W., Wei, L. L., Koh, H. Y., et al. (2016). Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26. Hepatology, 64(3), 797–813.PubMedCrossRef

45.

Pascut, D., Pratama, M. Y., Vo, N. V., Masadah, R., & Tiribelli, C. (2020). The crosstalk between tumor cells and the microenvironment in hepatocellular carcinoma: The role of exosomal microRNAs and their clinical implications. Cancers (Basel), 12(4), 823.PubMedCrossRef

46.

Yang, D., Wang, J., Xiao, M., Zhou, T., & Shi, X. (2016). Role of Mir-155 in controlling HIF-1α level and promoting endothelial cell maturation. Science and Reports, 6(1), 1–10.

47.

Chen, J. (2018). The prognostic analysis of different metastatic patterns in advanced liver cancer patients: A population based analysis. PLoS ONE, 13(8), e0200909.PubMedPubMedCentralCrossRef

48.

Zhang, J., Gu, C., Song, Q., Zhu, M., Xu, Y., Xiao, M., et al. (2020). Identifying cancer-associated fibroblasts as emerging targets for hepatocellular carcinoma. Cell & Bioscience, 10(1), 127. https://doi.org/10.1186/s13578-020-00488-yCrossRef

49.

Hu, W., Zheng, S., Guo, H., Dai, B., Ni, J., Shi, Y., et al. (2021). PLAGL2-EGFR-HIF-1/2α signaling loop promotes HCC progression and erlotinib insensitivity. Hepatology, 73(2), 674–691. https://doi.org/10.1002/hep.31293CrossRefPubMed

50.

Zhu, Y., Gao, X. M., Yang, J., Xu, D., Zhang, Y., Lu, M., et al. (2018). C-C chemokine receptor type 1 mediates osteopontin-promoted metastasis in hepatocellular carcinoma. Cancer Science, 109(3), 710–723. https://doi.org/10.1111/cas.13487CrossRefPubMedPubMedCentral

51.

Liu, Z., Wang, Y., Dou, C., Xu, M., Sun, L., Wang, L., et al. (2018). Hypoxia-induced up-regulation of VASP promotes invasiveness and metastasis of hepatocellular carcinoma. Theranostics, 8(17), 4649–4663. https://doi.org/10.7150/thno.26789CrossRefPubMedPubMedCentral

52.

Tian, X. P., Wang, C. Y., Jin, X. H., Li, M., Wang, F. W., Huang, W. J., et al. (2019). Acidic microenvironment up-regulates exosomal miR-21 and miR-10b in early-stage hepatocellular carcinoma to promote cancer cell proliferation and metastasis. Theranostics, 9(7), 1965–1979. https://doi.org/10.7150/thno.30958CrossRefPubMedPubMedCentral

53.

Huang, Z., Zhou, J.-K., Peng, Y., He, W., & Huang, C. (2020). The role of long noncoding RNAs in hepatocellular carcinoma. Molecular Cancer, 19(1), 77. https://doi.org/10.1186/s12943-020-01188-4CrossRefPubMedPubMedCentral

54.

Barth, D. A., Prinz, F., Teppan, J., Jonas, K., Klec, C., & Pichler, M. (2020). Long-noncoding RNA (lncRNA) in the regulation of hypoxia-inducible factor (HIF) in cancer. Non-Coding RNA, 6(3), 27.PubMedPubMedCentralCrossRef

55.

Zhang, Q., Cheng, Q., Xia, M., Huang, X., He, X., & Liao, J. (2020). Hypoxia-induced lncRNA-NEAT1 sustains the growth of hepatocellular carcinoma via regulation of miR-199a-3p/UCK2. Frontiers in Oncology, 10, 998. https://doi.org/10.3389/fonc.2020.00998CrossRefPubMedPubMedCentral

56.

Zhao, Z.-B., Chen, F., & Bai, X.-F. (2019). Long noncoding RNA MALAT1 regulates hepatocellular carcinoma growth under hypoxia via sponging microRNA-200a. Yonsei Medical Journal, 60(8), 727–734.PubMedPubMedCentralCrossRef

57.

Zeng, Z., Shi, Z., Liu, Y., Zhao, J., Lu, Q., Guo, J., et al. (2021). HIF-1α-activated TM4SF1-AS1 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells by enhancing TM4SF1 expression. Biochemical and Biophysical Research Communications, 566, 80–86. https://doi.org/10.1016/j.bbrc.2021.06.011CrossRefPubMed

58.

Hou, J., Zhang, H., Liu, J., Zhao, Z., Wang, J., Lu, Z., et al. (2019). YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma. Molecular Cancer, 18(1), 163. https://doi.org/10.1186/s12943-019-1082-3CrossRefPubMedPubMedCentral

59.

Yuen, V. W., & Wong, C. C. (2020). Hypoxia-inducible factors and innate immunity in liver cancer. The Journal of Clinical Investigation, 130(10), 5052–5062. https://doi.org/10.1172/jci137553CrossRefPubMedPubMedCentral

60.

Wu, Q., Zhou, W., Yin, S., Zhou, Y., Chen, T., Qian, J., et al. (2019). Blocking triggering receptor expressed on myeloid cells-1-positive tumor-associated macrophages induced by hypoxia reverses immunosuppression and anti-programmed cell death ligand 1 resistance in liver cancer. Hepatology, 70(1), 198–214.PubMedCrossRef

61.

Zhang, J., Zhang, Q., Lou, Y., Fu, Q., Chen, Q., Wei, T., et al. (2018). Hypoxia-inducible factor-1α/interleukin-1β signaling enhances hepatoma epithelial–mesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment. Hepatology, 67(5), 1872–1889.PubMedCrossRef

62.

Chiu, D.K.-C., Tse, A.P.-W., Xu, I.M.-J., Di Cui, J., Lai, R.K.-H., Li, L. L., et al. (2017). Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. Nature communications, 8(1), 1–12.CrossRef

63.

Niu, Y., Lin, Z., Wan, A., Sun, L., Yan, S., Liang, H., et al. (2021). Loss-of-function genetic screening identifies aldolase A as an essential driver for liver cancer cell growth under hypoxia. Hepatology, 74(3), 1461–1479.PubMedCrossRef

64.

Dong, F., Li, R., Wang, J., Zhang, Y., Yao, J., Jiang, S.-H., et al. (2021). Hypoxia-dependent expression of MAP17 coordinates the Warburg effect to tumor growth in hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research, 40(1), 1–15.CrossRef

65.

Miao, B., Wei, C., Qiao, Z., Han, W., Chai, X., Lu, J., et al. (2019). eIF3a mediates HIF1α-dependent glycolytic metabolism in hepatocellular carcinoma cells through translational regulation. American Journal of Cancer Research, 9(5), 1079.PubMedPubMedCentral

66.

Yang, N., Wang, T., Li, Q., Han, F., Wang, Z., Zhu, R., et al. (2021). HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1α. Journal of Cellular Physiology, 236(5), 3863–3880.PubMedCrossRef

67.

Zhou, Y., Huang, Y., Hu, K., Zhang, Z., Yang, J., & Wang, Z. (2020). HIF1A activates the transcription of lncRNA RAET1K to modulate hypoxia-induced glycolysis in hepatocellular carcinoma cells via miR-100-5p. Cell Death & Disease, 11(3), 1–14.CrossRef

68.

Chang, W. H., & Lai, A. G. (2020). The hypoxic tumour microenvironment: A safe haven for immunosuppressive cells and a therapeutic barrier to overcome. Cancer Letters, 487, 34–44.PubMedCrossRef

69.

Befani, C., & Liakos, P. (2018). The role of hypoxia-inducible factor-2 alpha in angiogenesis. Journal of Cellular Physiology, 233(12), 9087–9098.PubMedCrossRef

70.

Wang, S., Lu, J., You, Q., Huang, H., Chen, Y., & Liu, K. (2016). The mTOR/AP-1/VEGF signaling pathway regulates vascular endothelial cell growth. Oncotarget, 7(33), 53269.PubMedPubMedCentralCrossRef

71.

Feng, W., Xue, T., Huang, S., Shi, Q., Tang, C., Cui, G., et al. (2018). HIF-1α promotes the migration and invasion of hepatocellular carcinoma cells via the IL-8–NF-κB axis. Cellular & Molecular Biology Letters, 23(1), 1–8.CrossRef

72.

Zhu, B., Chen, S., Hu, X., Jin, X., Le, Y., Cao, L., et al. (2017). Knockout of the Nogo-B gene attenuates tumor growth and metastasis in hepatocellular carcinoma. Neoplasia, 19(7), 583–593.PubMedPubMedCentralCrossRef

73.

Cai, H., Saiyin, H., Liu, X., Han, D., Ji, G., Qin, B., et al. (2018). Nogo-B promotes tumor angiogenesis and provides a potential therapeutic target in hepatocellular carcinoma. Molecular Oncology, 12(12), 2042–2054.PubMedPubMedCentralCrossRef

74.

Korf-Klingebiel, M., Reboll, M. R., Klede, S., Brod, T., Pich, A., Polten, F., et al. (2015). Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction. Nature Medicine, 21(2), 140–149.PubMedCrossRef

75.

Wang, X., Mao, J., Zhou, T., Chen, X., Tu, H., Ma, J., et al. (2021). Hypoxia-induced myeloid derived growth factor promotes hepatocellular carcinoma progression through remodeling tumor microenvironment. Theranostics, 11(1), 209.PubMedPubMedCentralCrossRef

76.

Lin, X.-J., Fang, J.-H., Yang, X.-J., Zhang, C., Yuan, Y., Zheng, L., et al. (2018). Hepatocellular carcinoma cell-secreted exosomal microRNA-210 promotes angiogenesis in vitro and in vivo. Molecular Therapy-Nucleic Acids, 11, 243–252.PubMedPubMedCentralCrossRef

77.

Li, X., Li, X., Lv, X., Xiao, J., Liu, B., & Zhang, Y. (2017). Smad4 inhibits VEGF-A and VEGF-C expressions via enhancing Smad3 phosphorylation in colon cancer. The Anatomical Record, 300(9), 1560–1569.PubMedCrossRef

78.

Matsuura, Y., Wada, H., Eguchi, H., Gotoh, K., Kobayashi, S., Kinoshita, M., et al. (2019). Exosomal miR-155 derived from hepatocellular carcinoma cells under hypoxia promotes angiogenesis in endothelial cells. Digestive Diseases and Sciences, 64(3), 792–802.PubMedCrossRef

79.

Wu, W., He, X., Andayani, D., Yang, L., Ye, J., Li, Y., et al. (2017). Pattern of distant extrahepatic metastases in primary liver cancer: A SEER based study. Journal of Cancer, 8(12), 2312.PubMedPubMedCentralCrossRef

80.

Mohan, C. D., Bharathkumar, H., Dukanya Rangappa, S., Shanmugam, M. K., Chinnathambi, A., et al. (2018). N-substituted pyrido-1,4-oxazin-3-ones induce apoptosis of hepatocellular carcinoma cells by targeting NF-κB signaling pathway. Frontiers in Pharmacology, 9, 1125. https://doi.org/10.3389/fphar.2018.01125CrossRefPubMedPubMedCentral

81.

Yin, Z., Dong, C., Jiang, K., Xu, Z., Li, R., Guo, K., et al. (2019). Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma. Journal of Hematology & Oncology, 12(1), 101. https://doi.org/10.1186/s13045-019-0782-xCrossRef

82.

Yang, M. H., Mohan, C. D., Deivasigamani, A., Chinnathambi, A., Alharbi, S. A., Rangappa, K. S., et al. (2022). Procaine abrogates the epithelial-mesenchymal transition process through modulating c-Met phosphorylation in hepatocellular carcinoma. Cancers (Basel), 14(20), 4978.PubMedCrossRef

83.

Jung, Y. Y., Mohan, C. D., Eng, H., Narula, A. S., Namjoshi, O. A., Blough, B. E., et al. (2022). 2,3,5,6-Tetramethylpyrazine targets epithelial-mesenchymal transition by abrogating manganese superoxide dismutase expression and TGFβ-driven signaling cascades in colon cancer cells. Biomolecules, 12(7), 891.PubMedPubMedCentralCrossRef

84.

Cheng, J.-T., Wang, L., Wang, H., Tang, F.-R., Cai, W.-Q., Sethi, G., et al. (2019). Insights into biological role of LncRNAs in epithelial-mesenchymal transition. Cells, 8(10). https://doi.org/10.3390/cells8101178

85.

Wee, I., Syn, N., Sethi, G., Goh, B. C., & Wang, L. (2019). Role of tumor-derived exosomes in cancer metastasis. Biochimica et Biophysica Acta - Reviews on Cancer, 1871(1), 12–19. https://doi.org/10.1016/j.bbcan.2018.10.004CrossRefPubMed

86.

Sebastian, A., Pandey, V., Mohan, C. D., Chia, Y. T., Rangappa, S., Mathai, J., et al. (2016). Novel adamantanyl-based thiadiazolyl pyrazoles targeting EGFR in triple-negative breast cancer. ACS Omega, 1(6), 1412–1424. https://doi.org/10.1021/acsomega.6b00251CrossRefPubMedPubMedCentral

87.

Gurzu, S., Kobori, L., Fodor, D., & Jung, I. (2019). Epithelial mesenchymal and endothelial mesenchymal transitions in hepatocellular carcinoma: A review. BioMed Research International, 2019, 2962580. https://doi.org/10.1155/2019/2962580CrossRefPubMedPubMedCentral

88.

Chen, X., Zhang, S., Wang, Z., Wang, F., Cao, X., Wu, Q., et al. (2018). Supervillin promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma in hypoxia via activation of the RhoA/ROCK-ERK/p38 pathway. Journal of Experimental & Clinical Cancer Research, 37(1), 128. https://doi.org/10.1186/s13046-018-0787-2CrossRef

89.

Sheu, B. C., Chang, W. C., Cheng, C. Y., Lin, H. H., Chang, D. Y., & Huang, S. C. (2008). Cytokine regulation networks in the cancer microenvironment. Frontiers in Bioscience, 13, 6255–6268. https://doi.org/10.2741/3152CrossRefPubMed

90.

El-Tanani, M. K. (2008). Role of osteopontin in cellular signaling and metastatic phenotype. Frontiers in Bioscience, 13, 4276–4284. https://doi.org/10.2741/3004CrossRefPubMed

91.

Barreca, M. M., Zichittella, C., Alessandro, R., & Conigliaro, A. (2021). Hypoxia-induced non-coding RNAs controlling cell viability in cancer. International Journal of Molecular Sciences, 22(4), 1857.PubMedPubMedCentralCrossRef

92.

Li, Y., Chen, G., Yan, Y., & Fan, Q. (2019). CASC15 promotes epithelial to mesenchymal transition and facilitates malignancy of hepatocellular carcinoma cells by increasing TWIST1 gene expression via miR-33a-5p sponging. European Journal of Pharmacology, 860, 172589. https://doi.org/10.1016/j.ejphar.2019.172589CrossRefPubMed

93.

Ji, J., Rong, Y., Luo, C. L., Li, S., Jiang, X., Weng, H., et al. (2018). Up-regulation of hsa-miR-210 promotes venous metastasis and predicts poor prognosis in hepatocellular carcinoma. Frontiers in Oncology, 8, 569. https://doi.org/10.3389/fonc.2018.00569CrossRefPubMedPubMedCentral

94.

Hashemi, M., Hajimazdarany, S., Mohan, C. D., Mohammadi, M., Rezaei, S., Olyaee, Y., et al. (2022). Long non-coding RNA/epithelial-mesenchymal transition axis in human cancers: Tumorigenesis, chemoresistance, and radioresistance. Pharmacological Research, 186, 106535. https://doi.org/10.1016/j.phrs.2022.106535CrossRefPubMed

95.

Pan, X. Y., Huang, C., & Li, J. (2021). The emerging roles of m(6)A modification in liver carcinogenesis. International Journal of Biological Sciences, 17(1), 271–284. https://doi.org/10.7150/ijbs.50003CrossRefPubMedPubMedCentral

96.

Wang, B., Zhao, Q., Zhang, Y., Liu, Z., Zheng, Z., Liu, S., et al. (2021). Targeting hypoxia in the tumor microenvironment: A potential strategy to improve cancer immunotherapy. Journal of Experimental & Clinical Cancer Research, 40(1), 24. https://doi.org/10.1186/s13046-020-01820-7CrossRef

97.

Qin, W., Cao, Z.-Y., Liu, S.-Y., & Xu, X.-D. (2020). Recent advances regarding tumor microenvironment and immunotherapy in hepatocellular carcinoma. Hepatoma Research, 6, 24.

98.

Li, L., Yu, R., Cai, T., Chen, Z., Lan, M., Zou, T., et al. (2020). Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment. International Immunopharmacology, 88, 106939.PubMedCrossRef

99.

Khandia, R., & Munjal, A. (2020). Interplay between inflammation and cancer. Advances in Protein Chemistry and Structural Biology, 119, 199–245.PubMedCrossRef

100.

Fu, Y., Liu, S., Zeng, S., & Shen, H. (2019). From bench to bed: The tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research, 38(1), 396. https://doi.org/10.1186/s13046-019-1396-4CrossRef

101.

Mo, Z., Liu, D., Rong, D., & Zhang, S. (2021). Hypoxic characteristic in the immunosuppressive microenvironment of hepatocellular carcinoma. Frontiers in Immunology, 12, 611058. https://doi.org/10.3389/fimmu.2021.611058CrossRefPubMedPubMedCentral

102.

Veglia, F., & Gabrilovich, D. I. (2017). Dendritic cells in cancer: The role revisited. Current Opinion in Immunology, 45, 43–51. https://doi.org/10.1016/j.coi.2017.01.002CrossRefPubMedPubMedCentral

103.

Umezaki, N., Nakagawa, S., Yamashita, Y.-I., Kitano, Y., Arima, K., Miyata, T., et al. (2019). Lysyl oxidase induces epithelial-mesenchymal transition and predicts intrahepatic metastasis of hepatocellular carcinoma. Cancer Science, 110(6), 2033–2043. https://doi.org/10.1111/cas.14010CrossRefPubMedPubMedCentral

104.

Tcyganov, E., Mastio, J., Chen, E., & Gabrilovich, D. I. (2018). Plasticity of myeloid-derived suppressor cells in cancer. Current Opinion in Immunology, 51, 76–82.PubMedPubMedCentralCrossRef

105.

Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., et al. (2014). PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. Journal of Experimental Medicine, 211(5), 781–790.PubMedPubMedCentralCrossRef

106.

Xia, H., Chen, J., Gao, H., Kong, S. N., Deivasigamani, A., Shi, M., et al. (2020). Hypoxia-induced modulation of glucose transporter expression impacts 18F-fluorodeoxyglucose PET-CT imaging in hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 47(4), 787–797.PubMedCrossRef

107.

Lei, Y., Hu, Q., & Gu, J. (2020). Expressions of carbohydrate response element binding protein and glucose transporters in liver cancer and clinical significance. Pathology & Oncology Research, 26(2), 1331–1340.CrossRef

108.

Zhang, X., Guo, J., Kaboli, P. J., Zhao, Q., Xiang, S., Shen, J., et al. (2020). Analysis of key genes regulating the warburg effect in patients with gastrointestinal cancers and selective inhibition of this metabolic pathway in liver cancer cells. OncoTargets and therapy, 13, 7295.PubMedPubMedCentralCrossRef

109.

Yu, H., He, J., Liu, W., Feng, S., Gao, L., Xu, Y., et al. (2021). The Transcriptional Coactivator, ALL1-Fused Gene From Chromosome 9, Simultaneously Sustains Hypoxia Tolerance and Metabolic Advantages in Liver Cancer . Hepatology, 74(4), 1952–1970.

110.

Hu, M., Fu, Q., Jing, C., Zhang, X., Qin, T., & Pan, Y. (2020). LncRNA HOTAIR knockdown inhibits glycolysis by regulating miR-130a-3p/HIF1A in hepatocellular carcinoma under hypoxia. Biomedicine & Pharmacotherapy, 125, 109703.CrossRef

111.

Shao, S., Duan, W., Xu, Q., Li, X., Han, L., Li, W., et al. (2019). Curcumin suppresses hepatic stellate cell-induced hepatocarcinoma angiogenesis and invasion through downregulating CTGF. Oxidative Medicine and Cellular Longevity, 2019, 8148510.

112.

Zuo, H. X., Jin, Y., Wang, Z., Li, M. Y., Zhang, Z. H., Wang, J. Y., et al. (2020). Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer. Journal of Ethnopharmacology, 257, 112835.PubMedCrossRef

113.

Li, J., Wei, H., Liu, Y., Li, Q., Guo, H., Guo, Y., et al. (2020). Curcumin inhibits hepatocellular carcinoma via regulating miR-21/TIMP3 axis. Evidence-Based Complementary and Alternative Medicine, 2020, 2892917.

114.

Izzo, C., Annunziata, M., Melara, G., Sciorio, R., Dallio, M., Masarone, M., et al. (2021). The role of resveratrol in liver disease: A comprehensive review from in vitro to clinical trials. Nutrients, 13(3), 933.PubMedPubMedCentralCrossRef

115.

Lim, H. Y., Ong, P. S., Wang, L., Goel, A., Ding, L., Wong, A.L.-A., et al. (2021). Celastrol in cancer therapy: Recent developments, challenges and prospects. Cancer Letters, 521, 252–267.PubMedCrossRef

116.

Zhou, B., Yan, Z., Liu, R., Shi, P., Qian, S., Qu, X., et al. (2016). Prospective study of transcatheter arterial chemoembolization (TACE) with ginsenoside Rg3 versus TACE alone for the treatment of patients with advanced hepatocellular carcinoma. Radiology, 280(2), 630–639.PubMedCrossRef

117.

Ma, Z., Xiang, X., Li, S., Xie, P., Gong, Q., Goh, B.-C., et al (2022). Targeting hypoxia-inducible factor-1, for cancer treatment: Recent advances in developing small-molecule inhibitors from natural compounds. Seminars in Cancer Biology, 80, 379–390.

118.

Dai, Q., Yin, Q., Wei, L., Zhou, Y., Qiao, C., Guo, Y., et al. (2016). Oroxylin A regulates glucose metabolism in response to hypoxic stress with the involvement of Hypoxia-inducible factor-1 in human hepatoma HepG2 cells. Molecular Carcinogenesis, 55(8), 1275–1289.PubMedCrossRef

119.

Li, Y., Zhao, L., & Li, X.-F. (2021). Targeting hypoxia: Hypoxia-activated prodrugs in cancer therapy. Frontiers in Oncology, 11, 700407.

120.

Tran, N. H., Foster, N. R., Mahipal, A., Byrne, T., Hubbard, J., Silva, A., et al. (2021). Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). Investigational New Drugs, 39(4), 1072–1080.PubMedPubMedCentralCrossRef

121.

Abi-Jaoudeh, N., Dayyani, F., Chen, P. J., Fernando, D., Fidelman, N., Javan, H., et al. (2021). Phase I trial on arterial embolization with hypoxia activated tirapazamine for unresectable hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 8, 421.PubMedPubMedCentralCrossRef

122.

Schneider, M. A., Linecker, M., Fritsch, R., Muehlematter, U. J., Stocker, D., Pestalozzi, B., et al. (2021). Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors. Nature communications, 12(1), 1–12.CrossRef

123.

Wu, J., Contratto, M., Shanbhogue, K. P., Manji, G. A., O’Neil, B. H., Noonan, A., et al. (2019). Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma. World Journal of Clinical Oncology, 10(3), 149.PubMedPubMedCentralCrossRef

124.

Zhu, H., Wang, D.-D., Yuan, T., Yan, F.-J., Zeng, C.-M., Dai, X.-Y., et al. (2018). Multikinase inhibitor CT-707 targets liver cancer by interrupting the hypoxia-activated IGF-1R–YAP axis. Cancer Research, 78(14), 3995–4006.PubMedCrossRef

125.

Xu, J., Zheng, L., Chen, J., Sun, Y., Lin, H., Jin, R.-A., et al. (2017). Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals. Cell Death & Disease, 8(10), e3095–e3095.CrossRef

126.

Zhou, Y., Dong, X., Xiu, P., Wang, X., Yang, J., Li, L., et al. (2020). Meloxicam, a selective COX-2 inhibitor, mediates hypoxia-inducible factor-(HIF-) 1α signaling in hepatocellular carcinoma. Oxidative Medicine and Cellular Longevity, 2020, 7079308.

127.

Kashyap, D., Tuli, H. S., Yerer, M. B., Sharma, A., Sak, K., Srivastava, S., et al. (2021). Natural product-based nanoformulations for cancer therapy: Opportunities and challenges. Seminars in Cancer Biology, 69, 5–23. https://doi.org/10.1016/j.semcancer.2019.08.014CrossRefPubMed

128.

Zou, M.-Z., Liu, W.-L., Chen, H.-S., Bai, X.-F., Gao, F., Ye, J.-J., et al. (2021). Advances in nanomaterials for treatment of hypoxic tumor. National Science Review, 8(2), nwaa160.PubMedCrossRef

129.

Cavalli, R., Soster, M., & Argenziano, M. (2016). Nanobubbles: A promising efficienft tool for therapeutic delivery. Therapeutic delivery, 7(2), 117–138.PubMedCrossRef

130.

Moballegh Nasery, M., Abadi, B., Poormoghadam, D., Zarrabi, A., Keyhanvar, P., Khanbabaei, H., et al. (2020). Curcumin delivery mediated by bio-based nanoparticles: A review. Molecules, 25(3). https://doi.org/10.3390/molecules25030689

131.

Khan, M. S., Hwang, J., Lee, K., Choi, Y., Seo, Y., Jeon, H., et al. (2019). Anti-tumor drug-loaded oxygen nanobubbles for the degradation of HIF-1α and the upregulation of reactive oxygen species in tumor cells. Cancers (Basel), 11(10), 1464.PubMedCrossRef

132.

Li, H., Chen, J., Zen, W., Xu, X., Xu, Y., Chen, Q., et al. (2015). Effect of hypoxia inducible factor-1 antisense oligonucleotide on liver cancer. International Journal of Clinical and Experimental Medicine, 8(8), 12650.PubMedPubMedCentral

133.

Vanderborght, B., De Muynck, K., Lefere, S., Geerts, A., Degroote, H., Verhelst, X., et al. (2020). Effect of isoform-specific HIF-1α and HIF-2α antisense oligonucleotides on tumorigenesis, inflammation and fibrosis in a hepatocellular carcinoma mouse model. Oncotarget, 11(48), 4504.PubMedPubMedCentralCrossRef

134.

Mohan, C. D., Rangappa, S., Nayak, S. C., Jadimurthy, R., Wang, L., Sethi, G., et al. (2022). Bacteria as a treasure house of secondary metabolites with anticancer potential. Seminars in Cancer Biology, 86, 998–1013. https://doi.org/10.1016/j.semcancer.2021.05.006CrossRefPubMed

135.

Jadimurthy, R., Mayegowda, S. B., Nayak, S. C., Mohan, C. D., & Rangappa, K. S. (2022). Escaping mechanisms of ESKAPE pathogens from antibiotics and their targeting by natural compounds. Biotechnology Reports, 34, e00728. https://doi.org/10.1016/j.btre.2022.e00728CrossRefPubMedPubMedCentral

136.

Uzma, F., Mohan, C. D., Hashem, A., Konappa, N. M., Rangappa, S., Kamath, P. V., et al. (2018). Endophytic fungi—Alternative sources of cytotoxic compounds: A review. [Review]. Front Pharmacol, 9. https://doi.org/10.3389/fphar.2018.00309

137.

Mohan, C. D., Hari, S., Preetham, H. D., Rangappa, S., Barash, U., Ilan, N., et al. (2019). Targeting heparanase in cancer: Inhibition by synthetic, chemically modified, and natural compounds. iScience, 15, 360–390. https://doi.org/10.1016/j.isci.2019.04.034

138.

Siveen, K. S., Ahn, K. S., Ong, T. H., Shanmugam, M. K., Li, F., Yap, W. N., et al. (2014). Y-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model. Oncotarget, 5(7), 1897–1911. https://doi.org/10.18632/oncotarget.1876CrossRefPubMedPubMedCentral

139.

Merarchi, M., Sethi, G., Shanmugam, M. K., Fan, L., Arfuso, F., & Ahn, K. S. (2019). Role of natural products in modulating histone deacetylases in cancer. Molecules, 24(6), 1047.PubMedPubMedCentralCrossRef

140.

Patel, S. M., Nagulapalli Venkata, K. C., Bhattacharyya, P., Sethi, G., & Bishayee, A. (2016). Potential of neem (Azadirachta indica L.) for prevention and treatment of oncologic diseases. Seminars in Cancer Biology, 40–41, 100–115. https://doi.org/10.1016/j.semcancer.2016.03.002CrossRefPubMed

141.

Liu, C., Ho, P. C., Wong, F. C., Sethi, G., Wang, L. Z., & Goh, B. C. (2015). Garcinol: Current status of its anti-oxidative, anti-inflammatory and anti-cancer effects. Cancer Letters, 362(1), 8–14. https://doi.org/10.1016/j.canlet.2015.03.019CrossRefPubMed

142.

Manu, K. A., Shanmugam, M. K., Ramachandran, L., Li, F., Fong, C. W., Kumar, A. P., et al. (2012). First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway. Clinical Cancer Research, 18(8), 2220–2229. https://doi.org/10.1158/1078-0432.ccr-11-2470CrossRefPubMed

143.

Mohan, C. D., Rangappa, S., Preetham, H. D., Chandra Nayaka, S., Gupta, V. K., Basappa, S., et al. (2022). Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature. Seminars in Cancer Biology, 80, 157–182. https://doi.org/10.1016/j.semcancer.2020.03.016CrossRefPubMed

144.

Lee, J. H., Rangappa, S., Mohan, C. D., Basappa Sethi, G., Lin, Z.-X., et al. (2019). Brusatol, a Nrf2 inhibitor targets STAT3 signaling cascade in head and neck squamous cell carcinoma. Biomolecules, 9(10), 550.PubMedPubMedCentralCrossRef

145.

Lee, J. H., Mohan, C. D., Basappa, S., Rangappa, S., Chinnathambi, A., Alahmadi, T. A., et al. (2019). The IκB kinase inhibitor ACHP targets the STAT3 signaling pathway in human non-small cell lung carcinoma cells. Biomolecules, 9(12), 875.PubMedPubMedCentralCrossRef

146.

Baek, S. H., Ko, J. H., Lee, H., Jung, J., Kong, M., Lee, J. W., et al. (2016). Resveratrol inhibits STAT3 signaling pathway through the induction of SOCS-1: Role in apoptosis induction and radiosensitization in head and neck tumor cells. Phytomedicine, 23(5), 566–577. https://doi.org/10.1016/j.phymed.2016.02.011CrossRefPubMed

147.

Shanmugam, M. K., Ahn, K. S., Lee, J. H., Kannaiyan, R., Mustafa, N., Manu, K. A., et al. (2018). Celastrol attenuates the invasion and migration and augments the anticancer effects of bortezomib in a xenograft mouse model of multiple myeloma. Frontiers in Pharmacology, 9, 365. https://doi.org/10.3389/fphar.2018.00365CrossRefPubMedPubMedCentral

148.

Li, S., Yu, Y., Bian, X., Yao, L., Li, M., Lou, Y.-R., et al. (2021). Prediction of oral hepatotoxic dose of natural products derived from traditional Chinese medicines based on SVM classifier and PBPK modeling. Archives of Toxicology, 95(5), 1683–1701.PubMedCrossRef

Titel: Hypoxia signaling in hepatocellular carcinoma: Challenges and therapeutic opportunities
verfasst von: Shant Qinxiang Sin
Chakrabhavi Dhananjaya Mohan
Robby Miguel Wen-Jing Goh
Mingliang You
Siddaiah Chandra Nayak
Lu Chen
Gautam Sethi
Kanchugarakoppal Subbegowda Rangappa
Lingzhi Wang
Publikationsdatum: 22.12.2022
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 3/2023
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-022-10071-1

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Hypoxia signaling in hepatocellular carcinoma: Challenges and therapeutic opportunities

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Biographies

Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma

Oral delivery of RNAi for cancer therapy

New progress of tuberculosis scar carcinoma

Next-generation immune checkpoint inhibitors as promising functional molecules in cancer therapeutics

New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie